Clinical decision support (CDS) for drug-induced QT interval prolongation are being deployed across health systems; however, clinician adoption of CDS remains low. Identifying tangible factors that influence CDS adoption is critical to maximize the intended positive impact on patient care. We describe clinician adoption of a CDS for 11 drug-induced QT prolonging drugs and compare adoption between drugs with and without safe therapeutic alternatives.

Describe the new knowledge and additional skills the participant will gain after attending your presentation.: Compare the adoption of a CDS for drug-induced QT prolongation between drugs with and without safe therapeutic alternatives

Authors:

Katy Trinkley (Presenter)
University of Colorado

Jonathan Pell, University of Colorado
Michael Rosenberg, University of Colorado
CT Lin, University of Colorado
Dario Martinez, University of Colorado
Nicola Maude, University of Colorado
Sarah Scoular, University of Colorado
Miranda Kroehl, University of Colorado

Presentation Materials:

• Abstract/Manuscript - 1